News Releases

Summary Toggle Teligent, Inc. Announces First Quarter 2019 Results

BUENA, N.J. , May 06, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2019 . First Quarter 2019 Highlights Net revenues of $13.1 million for the first

May 6, 2019

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for First Quarter 2019 Results on Monday May 6th, 2019

BUENA, N.J. , May 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Monday May 6 th , 2019 to discuss the 1 st quarter 2019 financial results and business

May 2, 2019

PDF Version
Summary Toggle Teligent Provides Update on Orphan Drug Complete Response Letter

BUENA, N.J. , April 22, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced that on April 16, 2019 , its development partner has filed the response to the Complete Response Letter (“CRL”) it received on August 30 th ,

April 22, 2019

PDF Version
Summary Toggle Teligent, Inc. Management Comments on Recent Market Movements

BUENA, N.J. , April 12, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today provided commentary on the recent market movements in the price of its stock. “Teligent acknowledges that there have been significant negative

April 12, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Fluocinonide Cream USP, 0.1%

BUENA, N.J. , April 04, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

April 4, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Fluocinonide Topical Solution USP, 0.05%

BUENA, N.J. , March 19, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

March 19, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces Fourth Quarter and Year End 2018 Results

BUENA, N.J. , March 18, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the fourth quarter and year ended December 31, 2018 . Fourth Quarter 2018 Highlights Net revenues of $16.8 million

March 18, 2019

PDF Version
Summary Toggle Teligent, Inc. to Present at the 31st Annual ROTH Conference Tuesday March 19, 2019

BUENA, N.J. , March 15, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at 31 st Annual ROTH Conference March 19, 2019 . The Conference is taking place March 17 th - March 19 th , 2019 at the Ritz Carlton Laguna

March 15, 2019

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Desonide Ointment, 0.05%

BUENA, N.J. , March 14, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

March 14, 2019

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Fourth Quarter 2018 Results

BUENA, N.J. , March 12, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, announced the Company will hold a conference call at 8:00am ET on Monday, March 18 th , 2019 to discuss the 4 th quarter 2018 financial results and business

March 12, 2019

PDF Version